Raptor Pharmaceutical

USA

Raptor’s mission is to research, produce and deliver medicines that improve life for patients with severe, rare diseases. Raptor’s lead assets, RP103 and RP104, are proprietary delayed-release forms of cysteamine being developed for treatment of nephropathic cystinosis (NDA and MAA filed), Huntington’s disease (Phase 2/3), and non-alcoholic steatohepatitis (Phase 2b). 
  • Sector: Healthcare
  • Status: Public (NASDAQ: RPTP)
  • Geographic Market: U.S.
  • Investment Year: 2011
  • Investment Team: Ashley Friedman, Yuriy Prilutskiy

Visit the company’s website.